MedTrace Logo

The Incidence of Linezolid-induced Thrombocytopenia (LIT) in Critically Ill Patients, the Risk Factors for LIT

NCT05944445 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 310

Last updated 2023-07-17

No results posted yet for this study

Summary

* To identify the incidence of LIT among critically ill patients, as limited studies have only addressed this population.
* To evaluate the impact of several factors on the incidence of LIT, the time to onset of LIT, and the time to recovery of platelets.
* To study the effect of concurrent medications (enoxaparin, unfractinated heparin, piperacillin, carbapenems, tigecycline, fluconazole or voriconazole, digoxin, amiodarone, acetaminophen, tirofiban, statins, and antiepileptics) frequently used in critically ill patients on the incidence of LIT.
* To investigate the impact of possible medications with an antioxidant effect on the prevention of LIT.
* To assess the impact of LIT on composite end point (mortality, bleeding, and length of stay)

Conditions

  • Thrombocytopenia; Drugs

Interventions

DRUG

Linezolid 600 mg

Linezolid 600mg injection

Sponsors & Collaborators

  • Helwan University

    lead OTHER

Principal Investigators

  • Abdelhameed I Ebid · Helwan University, faculty of pharmacy

  • Mahmoud I Mostafa · Helwan University, faculty of pharmacy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-13
Primary Completion
2024-08-31
Completion
2024-08-31
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05944445 on ClinicalTrials.gov